NCT02095626View on ClinicalTrials.gov

Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
PGD Primary Graft Dysfunction
Interventions
DRUG

AP-301

orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days

DRUG

saline solution

placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days

Trial Locations (1)

1090

Division of Thoracic Surgery MedUni Vienna, Vienna

All Listed Sponsors
lead

Apeptico Forschung und Entwicklung GmbH

INDUSTRY

NCT02095626 - Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation | Biotech Hunter | Biotech Hunter